Webinar | April 12, 2023

Characterization Of Residual Impurities In Gene Therapy Drug Products

Characterization of residual impurities for gene therapy drug products is particularly challenging due to the complex nature of the final products as well as the complicated processes required to manufacture them. As these products advance through clinical development, the identification, characterization, and control of the process- and product-related impurities are important to define early on, and require careful assessment of impurity clearance and risk related to each impurity. This expert discussion focuses on risk assessment and characterization of product-related impurities in lentiviral vector-based gene therapy products.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online